Table 1.
Baseline Characteristics of All Patients Evaluated for HTx Eligibility (N = 343)
| Age (yrs) | 56 ± 14 |
| Male | 243 (71) |
| BMI (kg/m2) | 27.7 ± 5.6 |
| Diabetes | 75 (22) |
| Heart rate (beats/min) | 75.9 ± 14 |
| Systolic blood pressure (mm Hg) | 112 ± 19 |
| Diastolic blood pressure (mm Hg) | 72 ± 12 |
| Laboratory examination | |
| WBC (×103/μl) | 7.7 ± 2.1 |
| Hemoglobin (g/dl) | 13.6 ± 2.3 |
| Platelets (×103/μl) | 226 ± 71 |
| Serum sodium (mEq/l) | 138 ± 2.8 |
| BUN (mg/dl) | 25.3 ± 15 |
| Creatinine (mg/dl) | 1.3 ± 1.4 |
| Total bilirubin (mg/dl) | 0.9 ± 0.8 |
| AST (U/l) | 25 ± 12 |
| ALT (U/l) | 26 ± 15 |
| Albumin (g/dl) | 4.4 ± 0.5 |
| INR | 1.6 ± 0.8 |
| Total cholesterol (mg/dl) | 178 ± 51 |
| BNP (pg/ml) | 514 ± 814 |
| Medications | |
| ACE inhibitors | 215 (63) |
| ARBs | 55 (16) |
| Beta-blockers | 283 (83) |
| Statin | 140 (41) |
| Aldosterone antagonist | 136 (39) |
| Oral antidiabetic agents | 30 (8.7) |
| Insulin | 24 (7.0) |
| Prognostic factors | |
| Peak VO2 (ml/min/kg) | 12.9 ± 4.81 |
| HFSS | 7.45 ± 2.82 |
| SHFM | 0.43 ± 0.79 |
| Endpoint events count | 63 (26) |
| Endpoint events due to death | 18 (5.6) |
Values are mean ± SD or n (%).
ACE = angiotensin-converting enzyme; ALT = alanine aminotransferase; ARB = angiotensin receptor blockers; AST = aspartate aminotransferase; BMI = body mass index; BNP = B-type natriuretic peptide; BUN = blood urea nitrogen; HFSS = Heart Failure Survival Score; HTx = heart transplantation; INR = international normalized ratio; VO2 = oxygen consumption; SHFM = Seattle Heart Failure Model; WBC = white blood cells.